{
    "medicine_id": "b69d9680486df886ae8dc65bdcd0e5c4bb058890",
    "platform_id": "5507",
    "metadata": {
        "name": "Viramune 50 mg 5 ml oral suspension",
        "composition": "Each ml of oral suspension contains 10 mg of nevirapine as hemihydrate",
        "clinical_particulars": {
            "therapeutic_indications": "Viramune is indicated in combination with other anti retroviral medicinal products for the treatment of HIV 1 infected adults adolescents and children of any age see section 4 2 Most of the experience with Viramune is in combination with nucleoside reverse transcriptase inhibitors NRTIs The choice of a subsequent therapy after Viramune should be based on clinical experience and resistance testing see section 5 1",
            "contraindications": {
                "disease": "Hypersensitivity to the active substance or to any of the excipients listed in section 6 1 Readministration to patients who have required permanent discontinuation for severe rash rash accompanied by constitutional symptoms hypersensitivity reactions or clinical hepatitis due to nevirapine Patients with severe hepatic impairment Child Pugh C or pre treatment ASAT or ALAT 5 ULN until baseline ASAT ALAT are stabilised 5 ULN Readministration to patients who previously had ASAT or ALAT 5 ULN during nevirapine therapy and had recurrence of liver function abnormalities upon readministration of nevirapine see section 4 4 Coadministration with herbal preparations containing St John s wort Hypericum perforatum due to the risk of decreased plasma concentrations and reduced clinical effects of nevirapine see section 4 5",
                "pregnancy": "Applicable",
                "machine_ops": "Applicable",
                "excipients": "Carbomer;Methyl parahydroxybenzoate (E218);Propyl parahydroxybenzoate (E216);Sorbitol;Sucrose;Polysorbate 80;Sodium hydroxide (for pH-adjustment);Purified water",
                "incompatibilities": "Not applicable."
            }
        },
        "revision_date": "2022-08-12"
    }
}